Economic problem adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: a financial problem

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to September 2025, FDA received 15,202 adverse event reports that record the MedDRA preferred term Economic problem. In plain words, the term means: a financial problem. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 24 reports in the 12 months to June 2026 and 93 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,387 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 24 (under 0.1%) record this term. Reports for male patients were 45.9% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A financial problem. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 92 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Economic problem name as a suspect product, in order of name
Drug	Class	Reports with this term
Abilify	Atypical antipsychotic	1,520
Abilify Maintena		52
Acetaminophen Oxycodone Hydrochloride		19
Ambien	gamma-Aminobutyric acid A receptor positive modulator	10
Androderm		57
Androgel		1,019
Aripiprazole	Atypical antipsychotic	45
Atripla		1,447
Avandia		73
Avelox		10
Avonex	Interferon beta	24
Axiron		52
Buprenorphine	Partial opioid agonist	18
Celebrex	Nonsteroidal anti-inflammatory drug	43
Chantix	Partial cholinergic nicotinic agonist	18
Complera	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	400
Cymbalta		55
Depakote	Anti-epileptic agent	160
Depo-Testosterone	Androgen	39
Detrol	Cholinergic muscarinic antagonist	10
Digoxin	Cardiac glycoside	1,357
Dilantin	Anti-epileptic agent	10
Dilaudid	Opioid agonist	27
Dulcolax	Osmotic laxative	10
Effexor	Serotonin and norepinephrine reuptake inhibitor	20
Enbrel	Tumor necrosis factor blocker	55
Fentanyl	Opioid agonist	13
Forteo	Parathyroid hormone analog	10
Fortesta		20
Humira		48
Hydrocodone and Acetaminophen		13
Hydrocodone bitartrate and acetaminophen	Opioid agonist	13
Hydromorphone		20
Kaletra	Cytochrome P450 3A inhibitor	16
Keytruda	Programmed death Receptor-1 blocking antibody	19
Levaquin		20
Lipitor	HMG-CoA reductase inhibitor	45
Lyrica		13
Methadone hydrochloride	Opioid agonist	13
Metoclopramide	Dopamine-2 receptor antagonist	3,673
Metoclopramide hydrochloride	Dopamine-2 receptor antagonist	100
Mirapex		90
Mirena	Progestin	30
Morphine	Opioid agonist	18
Morphine sulfate	Opioid agonist	11
MS Contin	Opioid agonist	22
Neurontin		47
Norvasc	Calcium channel blocker	16
Nuvaring	Estrogen	13
Orencia	Selective T cell costimulation modulator	10
Oxycodone	Opioid agonist	41
Oxycodone and acetaminophen	Opioid agonist	18
Oxycodone hydrochloride	Opioid agonist	16
OxyContin	Opioid agonist	60
ParaGard T 380A	Copper-containing intrauterine device	709
Paxil	Serotonin reuptake inhibitor	30
Peg-Intron		10
Percocet	Opioid agonist	15
Plavix	P2Y12 platelet inhibitor	54
Prednisone	Corticosteroid	29
Proair Hfa		16
Propacet 100		15
Propoxyphene Hcl		14
Propoxyphene Napsylate W/Acetaminophen		15
Ranitidine	Histamine-2 receptor antagonist	16
Rebif	Interferon beta	32
Reglan	Dopamine-2 receptor antagonist	127
Requip		29
Rexulti	Atypical antipsychotic	27
Risperdal	Atypical antipsychotic	10
Seroquel	Atypical antipsychotic	15
Simvastatin	HMG-CoA reductase inhibitor	16
Stribild	Cytochrome P450 3A inhibitor	677
Suboxone	Opioid antagonist	22
Tacrolimus	Calcineurin inhibitor immunosuppressant	11
Tepezza		97
Testim	Androgen	184
Testopel	Androgen	23
Testosterone cypionate	Androgen	18
Topiramate		11
Tramadol		34
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	1,934
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	18
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	16
Vioxx		20
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	900
Vyvanse	Central nervous system stimulant	10
Xanax	Benzodiazepine	11
Xyrem	Central nervous system depressant	16
Zantac		46
Zoloft	Serotonin reuptake inhibitor	55
Zyrtec	Histamine-1 receptor antagonist	11

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 49 pharmacologic classes with 10 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Economic problem name, in order of name
Class	Reports with this term
Aminoketone	14
Androgen	266
Angiotensin 2 receptor blocker	14
Anti-epileptic agent	189
Atypical antipsychotic	1,646
Benzodiazepine	32
Bisphosphonate	25
Calcineurin inhibitor immunosuppressant	20
Calcium channel blocker	16
Cardiac glycoside	1,357
Central nervous system depressant	16
Central nervous system stimulant	25
Cholinergic muscarinic antagonist	10
Copper-containing intrauterine device	709
Corticosteroid	41
Cytochrome P450 3A inhibitor	701
Dopamine-2 receptor antagonist	3,900
Estrogen	23
Fluoroquinolone antibacterial	11
gamma-Aminobutyric acid A receptor positive modulator	16
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	913
Histamine-1 receptor antagonist	11
Histamine-2 receptor antagonist	19
HMG-CoA reductase inhibitor	67
Human immunodeficiency virus integrase strand transfer inhibitor	14
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	2,342
Insulin	10
Insulin analog	10
Interferon beta	56
Interleukin-17A antagonist	17
Kinase inhibitor	19
Nonergot dopamine agonist	12
Nonsteroidal anti-inflammatory drug	64
Opioid agonist	306
Opioid antagonist	22
Osmotic laxative	10
P2Y12 platelet inhibitor	54
Parathyroid hormone analog	10
Partial cholinergic nicotinic agonist	18
Partial opioid agonist	27
Potassium channel blocker	10
Progestin	37
Programmed death Receptor-1 blocking antibody	21
Proton pump inhibitor	38
Selective T cell costimulation modulator	10
Serotonin and norepinephrine reuptake inhibitor	60
Serotonin reuptake inhibitor	127
Thiazide diuretic	12
Tumor necrosis factor blocker	59

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Economic problem, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Economic problem
Age	Reports	Share
Under 2	4	under 0.1%
2 to 11	24	0.2%
12 to 17	23	0.2%
18 to 44	1,842	12.1%
45 to 64	3,181	20.9%
65 to 74	749	4.9%
75 and over	426	2.8%
Age not given	8,953	58.9%

Sex of the patient in the reports that record Economic problem
Sex	Reports	Share
Female	7,399	48.7%
Male	6,982	45.9%
Unknown or not given	821	5.4%

Age and sex are as the report gives them. 96.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Economic problem: adverse event reports that record this term. https://reportedreactions.com/reaction/economic-problem/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Economic problem mean in an adverse event report?

In plain words: a financial problem. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page